Memorial Sloan Kettering Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
- Conditions
- Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT03684980
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈDana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03681483
- Locations
- πΊπΈ
Miami Cancer Institute, Miami, Florida, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈLehigh Valley Health Network, Allentown, Pennsylvania, United States
Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship
- Conditions
- Breast Cancer Survivors
- Interventions
- Behavioral: Traditional Neurocognitive AssessmentsBehavioral: Online Cognitive Battery (Cogsuite)
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 441
- Registration Number
- NCT03674437
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
- Conditions
- Malignant Biliary Obstruction
- Interventions
- Behavioral: FACT-Hep
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 118
- Registration Number
- NCT03672019
- Locations
- πΊπΈ
Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- Conditions
- Head and Neck Squamous Cell CancerRecurrent Head and Neck Squamous Cell CancerMetastatic Head and Neck Squamous Cell Cancer
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03667482
- Locations
- πΊπΈ
Baptist Alliance MCI, Miami, Florida, United States
πΊπΈLehigh Valley Health Network, Allentown, Pennsylvania, United States
πΊπΈMemorial Sloan Kettering Nassau, Uniondale, New York, United States
Investigating the Impact of Proactive Palliative Care
- Conditions
- Locally Advanced Solid Tumor CancersMetastatic Solid Tumor Cancers
- Interventions
- Behavioral: Expectations Survey (CanCORS)Behavioral: Values Survey (Serious Illness Care Program)Behavioral: Functional Assessment of Cancer Therapy-General (FACT-G)Behavioral: NCCN Distress ThermometerBehavioral: Hospital Anxiety and Depression Scale (HADS)Behavioral: Quality of Communication (QOC)Behavioral: visits with a supportive care clinician
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT03667378
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03665155
- Locations
- πΊπΈ
Memorial Slaon-Kettering Cancer Center, New York, New York, United States
Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma
- Conditions
- Survivors of Unilateral Retinoblastoma
- Interventions
- Behavioral: BASC-3 surveyBehavioral: PROMIS survey
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03662776
- Locations
- πΊπΈ
Texas Children's Hospital (Data Collection), Houston, Texas, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Lesion Dosimetry with Iodine-124 in Metastatic Thyroid Carcinoma
- Conditions
- Thyroid CarcinomaMetastatic Thyroid Carcinoma
- Interventions
- Device: PET/CT ScanDrug: Iodine-124
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03647358
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈWeill Cornell Medical Center, New York, New York, United States
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
- Conditions
- Adenocarcinoma of Endometrium
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03643510
- Locations
- πΊπΈ
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States